BIOMAT Database Logo BIOMAT Database Logo

Exhaled Nitric Oxide in Systemic Sclerosis Lung Disease. 2017

Natalie K Kozij, and John T Granton, and Philip E Silkoff, and John Thenganatt, and Shobha Chakravorty, and Sindhu R Johnson
University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada.

Background. Exhaled nitric oxide (eNO) is a potential biomarker to distinguish systemic sclerosis (SSc) associated pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD). We evaluated the discriminative validity, feasibility, methods of eNO measurement, and magnitude of differences across lung diseases, disease-subsets (SSc, systemic lupus erythematosus), and healthy-controls. Methods. Consecutive subjects in the UHN Pulmonary Hypertension Programme were recruited. Exhaled nitric oxide was measured at 50 mL/s intervals using chemiluminescent detection. Alveolar and conducting airway NO were partitioned using a two-compartment model of axial diffusion (CMAD) and the trumpet model of axial diffusion (TMAD). Results. Sixty subjects were evaluated. Using the CMAD model, control subjects had lower median (IQR) alveolar NO than all PAH subjects (2.0 (1.5, 2.5) versus 3.14 ppb (2.3, 4.0), p = 0.008). SSc-ILD had significantly lower median conducting airway NO compared to controls (1009.5 versus 1342.1 ml⁎ppb/s, p = 0.04). SSc-PAH had increased median (IQR) alveolar NO compared to controls (3.3 (3.0, 5.7) versus 2.0 ppb (1.5, 2.5), p = 0.01). SSc-PAH conducting airway NO inversely correlated with DLCO (r -0.88 (95% CI -0.99, -0.26)). Conclusion. We have demonstrated feasibility, identified that CMAD modeling is preferred in SSc, and reported the magnitude of differences across cases and controls. Our data supports discriminative validity of eNO in SSc lung disease.

UI MeSH Term Description Entries
D008171 Lung Diseases Pathological processes involving any part of the LUNG. Pulmonary Diseases,Disease, Pulmonary,Diseases, Pulmonary,Pulmonary Disease,Disease, Lung,Diseases, Lung,Lung Disease
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009569 Nitric Oxide A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. Endogenous Nitrate Vasodilator,Mononitrogen Monoxide,Nitric Oxide, Endothelium-Derived,Nitrogen Monoxide,Endothelium-Derived Nitric Oxide,Monoxide, Mononitrogen,Monoxide, Nitrogen,Nitrate Vasodilator, Endogenous,Nitric Oxide, Endothelium Derived,Oxide, Nitric,Vasodilator, Endogenous Nitrate
D001944 Breath Tests Any tests done on exhaled air. Breathalyzer Tests,Breath Test,Breathalyzer Test,Test, Breath,Test, Breathalyzer,Tests, Breath,Tests, Breathalyzer
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012595 Scleroderma, Systemic A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA. Sclerosis, Systemic,Systemic Scleroderma,Systemic Sclerosis
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control

Related Publications

Natalie K Kozij, and John T Granton, and Philip E Silkoff, and John Thenganatt, and Shobha Chakravorty, and Sindhu R Johnson
Diagnostic value of exhaled nitric oxide to detect interstitial lung disease in systemic sclerosis.
July 2009, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG,
Natalie K Kozij, and John T Granton, and Philip E Silkoff, and John Thenganatt, and Shobha Chakravorty, and Sindhu R Johnson
Exhaled nitric oxide is elevated in patients with progressive systemic sclerosis without interstitial lung disease.
May 2001, Chest,
Natalie K Kozij, and John T Granton, and Philip E Silkoff, and John Thenganatt, and Shobha Chakravorty, and Sindhu R Johnson
Prognostic Role of Exhaled Breath Condensate pH and Fraction Exhaled Nitric Oxide in Systemic Sclerosis Related Interstitial Lung Disease.
March 2017, Archivos de bronconeumologia,
Natalie K Kozij, and John T Granton, and Philip E Silkoff, and John Thenganatt, and Shobha Chakravorty, and Sindhu R Johnson
Exhaled nitric oxide in systemic sclerosis: relationships with lung involvement and pulmonary hypertension.
July 2000, The Journal of rheumatology,
Natalie K Kozij, and John T Granton, and Philip E Silkoff, and John Thenganatt, and Shobha Chakravorty, and Sindhu R Johnson
Increased exhaled nitric oxide precedes lung fibrosis in two murine models of systemic sclerosis.
June 2015, Journal of breath research,
Natalie K Kozij, and John T Granton, and Philip E Silkoff, and John Thenganatt, and Shobha Chakravorty, and Sindhu R Johnson
Increased nitric oxide in exhaled air in patients with systemic sclerosis.
January 1998, Clinical and experimental rheumatology,
Natalie K Kozij, and John T Granton, and Philip E Silkoff, and John Thenganatt, and Shobha Chakravorty, and Sindhu R Johnson
Exhaled nitric oxide in pulmonary arterial hypertension associated with systemic sclerosis.
December 2016, Pulmonary circulation,
Natalie K Kozij, and John T Granton, and Philip E Silkoff, and John Thenganatt, and Shobha Chakravorty, and Sindhu R Johnson
Exhaled nitric oxide and pulmonary response to iloprost in systemic sclerosis.
August 1998, Lancet (London, England),
Natalie K Kozij, and John T Granton, and Philip E Silkoff, and John Thenganatt, and Shobha Chakravorty, and Sindhu R Johnson
Exhaled nitric oxide, but not serum nitrite and nitrate, is a marker of interstitial lung disease in systemic sclerosis.
May 2009, Nitric oxide : biology and chemistry,
Natalie K Kozij, and John T Granton, and Philip E Silkoff, and John Thenganatt, and Shobha Chakravorty, and Sindhu R Johnson
Exhaled nitric oxide levels in systemic sclerosis with and without pulmonary involvement.
August 2007, Chest,
Copied contents to your clipboard!